Verition Fund Management
STML

Verition Fund Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Verition Fund Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-35,000
Closed -$364K – 1475
2019
Q3 		$364K Buy
+35,000
New +$458K 0.01% 748

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Verition Fund Management's STML Position: Q4 2019 in Review

Verition Fund Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 35,000 shares — an estimated $364K sold.

Verition Fund Management first reported a position in STML in Q3 2019 and held it in 1 quarter. The position peaked at $364K in Q3 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

  • Verition Fund Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Verition Fund Management sold 35,000 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $364K.
  • Verition Fund Management first reported a position in Stemline Therapeutics, Inc. in Q3 2019 and held it in 1 quarter.
  • Verition Fund Management's Stemline Therapeutics, Inc. position peaked at $364K in Q3 2019.
  • 99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Verition Fund Management's 13F filing for Q4 2019, filed 14 Feb 2020.